A JOURNEY OF RESEARCH AND PROGRESS POWERED BY YOU

1987–1996
Genetic causes identified for types 1A, 1B, 1D, X1 (aka CMT1X/CMTX), and HNPP.

1983
CMTA founded by a group of CMT families and physicians.

2008
CMTA Launches Strategy To Accelerate Research (CMTA-STAR)

2006
Joining forces with the MDA, CMTA funds the first-ever ascorbic acid clinical trials.



2010
CMTA brings together global CMT experts for Type 2 Research Symposium

2009
In less than 1 year, the first CMT1A cell line is grown, and drug discovery for 1A begins at NIH.

2018
Gene therapy summit results in multi-year, multi-partner initiative to test drugs to slow axon degeneration. Patients as Partners in Research launched and accelerates patient-focused drug development.

2017
CMTA begins a multi-year, multi-partner initiative to test drugs targeting axon degeneration in CMT models.



2020
SORD gene discovered, and development heads rapidly toward CMT-SORD clinical trials with a CMTA Alliance Partner. Active genetic therapy projects ongoing for 1A, X , 2A, 2E, 2F, 4A and 4C.

2024
Phase III data for CMT-SORD released. CMTA and INC form exclusive alliance to accelerate research and provide key tools for drug developers.

2025
In a landmark year, **four clinical trials** ongoing with key support from CMTA in different CMT subtypes. CMTA-STAR supports **more than 50 active research projects, 34 companies** have used CMTA's stem cell lines, and **greater than 130 biopharma partner** connections have been made.

You've brought us this far. Will you help fuel what's next?

MAKE YOUR GIFT TODAY AT
cmtausa.org/supportstar

CMTA
Charcot-Marie-Tooth Association

STAR
Strategy To Accelerate Research